Page 581 - Hematology_ Basic Principles and Practice ( PDFDrive )

496 Part V Red Blood Cells

4. Theurl I, Mattle V, Seifert M, et al: Dysregulated monocyte iron homeo- 17. Ashby DR, Gale DP, Busbridge M, et al: Erythropoietin administration
stasis and erythropoietin formation in patients with anemia of chronic in humans causes a marked and prolonged reduction in circulating
disease. Blood 107:4142–4148, 2006. hepcidin. Haematologica 95:505–508, 2010.
5. Sun CC, Vaja V, Babitt JL, et al: Targeting the hepcidin-ferroportin axis 18. Kautz L, Jung G, Nemeth E, et al: Erythroferrone contributes to recovery
to develop new treatment strategies for anemia of chronic disease and from anemia of inflammation. Blood 124:2569–2574, 2014.
anemia of inflammation. Am J Hematol 87:392–400, 2012. 19. Cullis JO: Diagnosis and management of anaemia of chronic disease:
6. Thomas C, Thomas L: Anemia of chronic disease: pathophysiology and current status. Brit J Haematol 154:289–300, 2011.
laboratory diagnosis. Lab Hematol 11:14–23, 2005. 20. Skikne BS, Punnonen K, Caldron PH, et al: Improved differential
7. Theurl I, Theurl M, Seifert M, et al: Autocrine formation of hepcidin diagnosis of anemia of chronic disease and iron deficiency anemia: a
induces iron retention in human monocytes. Blood 111:2392–2399, prospective multicenter evaluation of soluble transferrin receptor and
2008. the sTfR/log ferritin index. Am J Hematol 86:923–927, 2011.
8. Raj DS: Role of interleukin-6 in the anemia of chronic disease. Semin 21. Brugnara C, Schiller B, Moran J: Reticulocyte hemoglobin equivalent
Arthritis Rheum 38:382–388, 2009. (Ret He) and assessment of iron-deficient states. Clin Lab Haematol
9. Andrews NC: Anemia of inflammation: the cytokine-hepcidin link. J 28:303–308, 2006.
Clin Invest 113:1251–1253, 2004. 22. Viele MK, Weiskopf RB: What can we learn about the need for transfu-
10. Oppenheimer SJ: Iron and its relation to immunity and infectious sion from patients who refuse blood? The experience with Jehovah’s
disease. J Nutr 131:616S–633S, 2001. Witnesses. Transfusion 34:396–401, 1994.
11. Ganz T: Hepcidin, a key regulator of iron metabolism and mediator of 23. Samaras AT, Bennett CL: Risks of venous thromboembolism and mortal-
anemia of inflammation. Blood 102:783–788, 2003. ity associated with erythropoiesis-stimulating agents for the treatment of
12. Fleming RE, Sly WS: Hepcidin: a putative iron-regulatory hormone cancer-associated anemia. Am J Hematol Oncol 7:327–332, 2008.
relevant to hereditary hemochromatosis and the anemia of chronic 24. Sanz Ortiz J: Predictors of response to erythropoiesis-stimulating agents
disease. Proc Natl Acad Sci USA 98:8160–8162, 2001. (ESA) in cancer patients: the role of baseline serum epoetin level. Clin
13. Wrighting DM, Andrews NC: Interleukin-6 induces hepcidin expression Transl Oncol 10:486–492, 2008.
through STAT3. Blood 108:3204–3209, 2006. 25. Sasu BJ, Cooke KS, Arvedson TL, et al: Antihepcidin antibody treat-
14. Richardson CL, Delehanty LL, Bullock GC, et al: Isocitrate ameliorates ment modulates iron metabolism and is effective in a mouse model of
anemia by suppressing the erythroid iron restriction response. J Clin inflammation-induced anemia. Blood 115:3616–3624, 2010.
Invest 123:3614–3623, 2013. 26. Song SN, Tomosugi N, Kawabata H, et al: Down-regulation of hepcidin
15. Bullock GC, Delehanty LL, Talbot AL, et al: Iron control of erythroid resulting from long-term treatment with an anti-IL-6 receptor antibody
development by a novel aconitase-associated regulatory pathway. Blood (tocilizumab) improves anemia of inflammation in multicentric Castle-
116:97–108, 2010. man disease. Blood 116:3627–3634, 2010.
16. de Bruin AM, Demirel O, Hooibrink B, et al: Interferon-gamma impairs
proliferation of hematopoietic stem cells in mice. Blood 121:3578–3585,
2013.